Synergy Pharmaceuticals to Give Plenary Presentation at the 16th Annual
NEW YORK -- May 12, 2014
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), today announced its Chief
Scientific Officer, Kunwar Shailubhai, PhD, MBA, will give a plenary
presentation at the 16^th Annual TIDES Summit being held May 12-15, in
Providence Rhode Island.
The session titled, “Guanylate Cyclase-C Agonists for Treatment of
Gastrointestinal Disorders and Inflammatory Bowel Diseases”, will be on
Thursday, May 15^th from 11:45am – 12:15pm (EDT) at the Providence Rhode
Island Convention Center.
The presentation will focus on the natural human gastrointestinal hormone,
uroguanylin, and its pharmacological role as agonist for the intestinal
guanylate cyclase-C (GC-C) receptor. The GC-C receptor is known to be a key
source for stimulating a variety of beneficial physiological responses.
About Synergy Pharmaceuticals Inc.
Synergy is a biopharmaceutical company focused on the development of novel
therapies based on the natural human hormone, uroguanylin, to treat
gastrointestinal diseases and disorders. Uroguanylin is a natural hormone
produced by humans in the small intestine and plays a key role in regulating
the normal functioning of the digestive tract through its activity on the
guanylate cyclase-C (GC-C) receptor. Synergy has created two unique analogs of
uroguanylin – plecanatide and SP-333 – designed to mimic the natural hormone’s
activity on the GC-C receptor and target a variety of gastrointestinal
conditions. For more information, please visit www.synergypharma.com
Synergy Pharmaceuticals Inc.
Press spacebar to pause and continue. Press esc to stop.